PMID- 34608021
OWN - NLM
STAT- MEDLINE
DCOM- 20211129
LR  - 20230921
IS  - 1536-5409 (Electronic)
IS  - 0749-8047 (Print)
IS  - 0749-8047 (Linking)
VI  - 37
IP  - 12
DP  - 2021 Dec 1
TI  - Relative Efficacy and Safety of Tanezumab for Osteoarthritis: A Systematic Review 
      and Meta-analysis of Randomized-Controlled Trials.
PG  - 914-924
LID - 10.1097/AJP.0000000000000986 [doi]
AB  - OBJECTIVES: The aim of this meta-analysis was to evaluate the efficacy and safety 
      of tanezumab for the treatment of patients with knee or hip osteoarthritis (OA). 
      METHODS: PubMed, Embase, Cochrane Central Register of Controlled Trials, and Web 
      of Science were searched from inception to July 2020. Randomized-controlled 
      trials comparing tanezumab with placebo or nonsteroidal anti-inflammatory drugs 
      in patients with OA. Two investigators identified studies and independently 
      extracted data, and conventional meta-analyses were conducted with Review Manager 
      5.3. The outcomes were pain relief, functional improvement, and risk of adverse 
      events (AEs). RESULTS: A total of 8 articles, comprising 9 randomized-controlled 
      trials, were included. Overall, tanezumab was superior to placebo for relieving 
      pain and improving function, as well as in the patient's global assessment. 
      Tanezumab also had significant advantages over nonsteroidal anti-inflammatory 
      drugs for relieving pain and improving function, as well as in the patient's 
      global assessment. Significantly more patients discontinued treatment because of 
      AEs after treatment with tanezumab. However, the differences in serious AEs and 
      total joint replacement were not significant. Moreover, tanezumab-treated 
      patients experienced significantly more rapid progression of osteoarthritis. 
      DISCUSSION: Tanezumab can alleviate pain and improve function for patients with 
      OA of the hip or knee. Although tanezumab does not cause serious AEs, rapid 
      progression of OA occurred in a small number of participants, so more clinical 
      trials are needed to explore its safety.
CI  - Copyright (c) 2021 The Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Zhang, Bocheng
AU  - Zhang B
AD  - Second Affiliated Hospital.
AD  - Graduate School, Dalian Medical University.
FAU - Tian, Xiaoyuan
AU  - Tian X
AD  - Second Affiliated Hospital.
AD  - Graduate School, Dalian Medical University.
FAU - Qu, Zhenan
AU  - Qu Z
AD  - Affiliated Zhongshan Hospital, Dalian University, Dalian, Liaoning, China.
FAU - Liu, Jiaming
AU  - Liu J
AD  - Graduate School, Dalian Medical University.
FAU - Yang, Liang
AU  - Yang L
AD  - Second Affiliated Hospital.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Clin J Pain
JT  - The Clinical journal of pain
JID - 8507389
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - EQL0E9GCX1 (tanezumab)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized
MH  - Double-Blind Method
MH  - Humans
MH  - *Osteoarthritis, Knee/drug therapy
MH  - Pain Measurement
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
PMC - PMC8579990
COIS- The authors declare no conflict of interest.
EDAT- 2021/10/06 06:00
MHDA- 2021/11/30 06:00
PMCR- 2021/11/10
CRDT- 2021/10/05 05:50
PHST- 2021/03/22 00:00 [received]
PHST- 2021/09/03 00:00 [accepted]
PHST- 2021/10/06 06:00 [pubmed]
PHST- 2021/11/30 06:00 [medline]
PHST- 2021/10/05 05:50 [entrez]
PHST- 2021/11/10 00:00 [pmc-release]
AID - 00002508-202112000-00008 [pii]
AID - 10.1097/AJP.0000000000000986 [doi]
PST - ppublish
SO  - Clin J Pain. 2021 Dec 1;37(12):914-924. doi: 10.1097/AJP.0000000000000986.